Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing MATRix as remission induction in newly diagnosed primary CNS lymphoma
2024-514473-21-00Phase 3Authorised
- Sponsor
- Klinikum Stuttgart
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of methotrexate, cytarabine, thiotepa, rituximab, carmustine and 1 more in primary central nervous system lymphoma (PCNSL) and Diffuse Large B-Cell Primary Central Nervous System Lymphoma (2 arms), sponsored by Klinikum Stuttgart. Primary endpoint: Event-free survival. Planned start Jun 2021; status: authorised.
02
Drugs
methotrexatecytarabinethioteparituximabcarmustine
03
Conditions
primary central nervous system lymphoma (PCNSL)Diffuse Large B-Cell Primary Central Nervous System Lymphoma
Beyond the preview
Go deeper on 2024-514473-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514473-21-00.